Page 2514 - Williams Hematology ( PDFDrive )

2485
2484 Index Index 2485

Pseudo-Zollinger-Ellison syndrome, iron clinical features, 2269 posttransfusion, 2359, 2361
deficiency and, 629 complications, 2269 vascular. See Vascular purpuras
PSGL-1, 1852f, 1854, 1855–1856, 1870, definition and epidemiology, 2267 Purpura fulminans, 2104, 2207
1976–1977, 1977t, 1979t differential diagnosis, 2270 PUVA (psoralen plus ultraviolet A), 433,
PSMD4, 1736 etiology and pathogenesis, 2268 1686, 1687, 1689
Psoralen plus ultraviolet A (PUVA), 433, in hepatic disease, 2194–2195 PV. See Polycythemia vera (PV)
1106, 1686, 1687, 1689 objective testing for, 2271–2273 PYD (pyridinoline), 1738
Psoriasis, 1575 therapy. See Venous thrombosis/ Pyoderma gangrenosum, 2100, 2100f, 2102
Psychotropic drugs, 2079 thromboembolism, therapy Pyrazinamide, for tuberculosis, 386
PT. See Prothrombin time (PT) Pulmonary eosinophilia, 949–950 Pyridinoline (PYD), 1738
PTCL. See Peripheral T-cell lymphoma Pulmonary hypertension Pyridoxine, 651, 917–918, 920
(PTCL) chronic thromboembolic, 2273 Pyrimethamine, 606t, 1269
PTEN, 195, 1443 in polycythemia vera, 1293 Pyrimidine 5′-nucleotidase, 692t, 699, 700t,
PTEN, 231t, 1626, 1736t in primary myelofibrosis, 1324–1325 706, 706f
Pteroic acid, 584 vs. primary myelofibrosis, 1327–1328 Pyrimidine analogues, megaloblastic anemia
Pteroylglutamic acid (folic acid), 584, 585f. sickle cell disease and, 769 and, 606t
See also Folate treatment, 797 Pyrimidine synthesis, 587f
PTGS1/COX1, 1456 Punctate basophilia, 468 Pyrin, 298–299
PTLD (posttransplant lymphoproliferative Pure erythroid leukemia, 1390 PYRIN, 1025
disorders), 1265–1266, 1500t, 1574, Pure red cell aplasia Pyropoikilocytes, 475
1636 acquired, 542–545 Pyropoikilocytosis, hereditary. See Hereditary
PTP (posttransfusion purpura), 2359, 2361 in chronic lymphocytic leukemia, pyropoikilocytosis
PTPN11, 1346t, 1352, 1471 1542 Pyrrole rings, 892f
PTPN12, 1699 clinical features, 543–544 Pyruvate kinase (PK)
PTPRD, 234t definition and history, 542–543 activity, 692t
PTPs (protein tyrosine phosphatases), 253 differential diagnosis, 544 erythrocyte aging and, 497
PU.1 etiology and pathogenesis, 543 in glucose metabolism, 696
in B cell function, 271 laboratory features, 544 mutants/variants, 702
in erythroid differentiation, 272, 483 in large granular lymphocytic leukemia, structure, 696, 696f
GATA1 and, 268, 483 1566 Pyruvate kinase (PK) deficiency
in hematopoietic stem cell to common parvovirus B19 infection and, in animals, 704
lymphoid progenitor commitment, 1251–1252 clinical features, 690, 700t
262 therapy, course, and prognosis, 544–545, diagnosis, 700t
in lymphopoiesis, 1155 545f, 1542 differential diagnosis, 691
in myelopoiesis, 1011 classification of, 542t epidemiology, 690
RB and, 217 inherited (Diamond-Blackfan anemia), genetics, 702, 704
Pulmonary angiography, 2272 539–540, 994 in hereditary nonspherocytic hemolytic
Pulmonary disease/dysfunction during pregnancy, 120 anemia, 709
in acute myelogenous leukemia, 1381 transient aplastic crisis and transient malaria resistance and, 704
in adult Langerhans cell histiocytosis, 1108 erythroblastopenia of childhood, therapy, 711–712
anemia and, 505 541–542, 541f
in antiphospholipid syndrome, 2240 Pure white cell aplasia, 995 Q
in disseminated intravascular coagulation, Purine analogues, 322–324. See also specific 22q 11.2 deletion syndrome (DiGeorge
2204–2205, 2205t drugs syndrome), 86–87, 1214t, 1222
erythrocytosis of, 872, 875, 881 adverse effects, 324 Q43P, 1838
in Gaucher disease, 1124 mechanism of action, 323 3q abnormalities, 1377
Hodgkin lymphoma treatment and lung megaloblastic anemia and, 606t 5q-minus syndrome, 1312, 1347, 1347f
cancer risk, 1618 for mycosis fungoides, 1687 Quat Sha, 2107
after hematopoietic cell transplantation, pharmacology, 323–324 Quebec platelet syndrome/disorder, 1853,
368 structure, 323f 1854, 2055–2056, 2138
in Langerhans cell histiocytosis, 1104 Purine nucleoside phosphorylase deficiency, Quinacrine, aplastic anemia and, 515
primary lymphoma, 1581 1214t, 1217 Quinidine, 2017, 2079
in sickle cell disease, 768–769, 769f Purine synthesis, 585, 586t, 587f Quinine, 817, 819, 2015, 2017, 2245, 2262
in Waldenström macroglobulinemia, 1791 Purpura Quinolones, 384, 388–389
Pulmonary embolism. See also Venous amyloid, 1774, 1774f Quinupristin/dalfopristin, 385
thrombosis/thromboembolism in immune thrombocytopenia, 2002 Quizartinib, 1403

Kaushansky_index_p2393-2506.indd 2485 9/21/15 3:22 PM